Explore more Johnson & Johnson sites:
Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Clinical Trials Here
Learn More
Share
Ebola
When you're the CFO of a company, you have a holistic view of how a pandemic can touch every aspect of a business, especially when it's a healthcare company. So we posed inquiring mind questions to Joe Wolk about what the past eight months have been like for him at the financial helm of the company—via a Zoom interview.
From epidemic masks that the company introduced during the Spanish flu pandemic to work it's doing today on an investigational COVID-19 vaccine, learn how the company has been at the forefront of safeguarding global public health for well over a century.
The company is proud to have made the list for the second year in a row. From its work on an Ebola vaccine—and an investigational COVID-19 vaccine—to collaboration taking place across its Johnson & Johnson Innovation centers, we take a look at the innovative spirit that permeates the company's culture.
As the company announces the launch of its global Phase 3 clinical trial in approximately 60,000 participants on three continents, we share the most up-to-date information about the investigational vaccine candidate.
The clinical trial has completed full immunizations of the company's investigational HIV vaccine regimen. Learn what this means for the future of fighting the disease—and also for the creation of a potential vaccine for COVID-19.
As the European Commission grants Marketing Authorization for the company's Ebola vaccine regimen—a key step towards enabling broader access to it for the people who need it most—we share top facts about the vaccine for the deadly virus.
Imagine being a researcher who is staring down not only a highly infectious virus, but one that's caused the first global pandemic in more than 100 years. Meet Johnson & Johnson's Hanneke Schuitemaker, Ph.D.
Roland Zahn, Ph.D., a Janssen scientist and expert in viral vaccines, was at the front lines of research during the Ebola outbreak. Today he and his team are working at record speed to help deliver a potential vaccine for the novel coronavirus.
The coronavirus has made headlines as it has spread from China to other parts of the world. To help stop the global outbreak in its tracks, Johnson & Johnson is already hard at work on a potential preventive vaccine.
Innovativeness and a commitment to social responsibility are just some of the respected attributes that helped the company land on the prestigious list for another year.
From a first-of-its-kind contact lens that darkens when exposed to bright light to the first donation of 500,000 doses of an Ebola vaccine, here are just some of the ways Johnson & Johnson helped change the trajectory of health for humanity this past year.
The company has committed to donate up to 500,000 doses of an investigational Janssen vaccine regimen to help protect citizens of the Democratic Republic of the Congo—the site of the world's second largest outbreak of the disease.
Macaya Douoguih volunteered to lead an accelerated clinical program for a new investigational Ebola vaccine at the height of the 2014 epidemic in West Africa. She reflects on her experiences—and why her work must continue today.
These up-and-coming stars in oncology, immunology, anti-aging, vaccines and other areas of research are helping to change healthcare as we know it. And they're just at the beginning of their brilliant careers.
Cancer. HIV/AIDS. Ebola. These are just some of the causes these under-30 movers and shakers plan to impact with their bright ideas for change at a one-of-a-kind summit in Colombia.
